

# DEAL PROFILE

## Pharmanovia acquires 11 CNS Brands from Sanofi

September 18, 2023



### Pharmanovia

Headquartered in Basildon, England, Pharmanovia specializes in acquiring, developing and marketing mature branded medicines globally. It focuses on prescription medicines without patent protection in the fields of cardiovascular, women's health and endocrinology, neurology, and gastroenterology.

**Year Founded:** 2013      **# of Products:** 18      **# of Employees:** 280



### Sanofi S.A. (PAR: SAN)

Headquartered in Paris, France, Sanofi is an innovative global healthcare company developing and marketing first-in-class and best-in-class drugs in oncology, immunology, diabetes, and vaccines.

**TEV:** \$151B      **LTM EBITDA:** \$15B      **# of Employees:** 92,000

VALUES

Not Disclosed

Transaction Value

11

Brands

60+


Markets

## OVERVIEW

On September 18, 2023, Pharmanovia announced the acquisition of 11 central nervous system (CNS) branded pharmaceutical products from Sanofi for an undisclosed sum. The portfolio spans over 60 markets including Brazil, South Africa, France, and Italy, which will strengthen Pharmanovia's CNS footprint in these territories. The deal includes leading brands such as Frisium® (*clobazam*) and Gardenal® (*phenobarbital*) for the treatment of epilepsy.

## HIGHLIGHTS

Sanofi's divestiture of non-core CNS assets follows two similar deals last year; it sold 17 products to Neuraxpharm for an undisclosed sum, and then returned Regeneron the full rights to oncology drug Libtayo® in exchange for \$900M. The French group is executing on its strategy of focusing on first-in-class or best-in-class assets, while riding the wave of blockbuster sales from immunology drug Dupixent®. On the other hand, Pharmanovia was rumored to be the target of a \$1.5B buyout in May 2023, but now seems to be continuing to deliver on its strategy of lifecycle management and expansion to new geographies.



## BOURNE PARTNERS MARKET RESEARCH

Bourne Partners provides strategic and financial advisory services to clients throughout the business evolution life cycle. In order to provide the highest level of service, we routinely analyze relevant industry trends and transactions. These materials are available to our clients and partners and provide detailed insight into the pharma, pharma services, OTC, consumer health, and biotechnology sectors.